LeMaitre Vascular, Inc. (LMAT)
USD 90.34
(-0.65%)
USD 90.34
(-0.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 37.08 Million USD | 75.21% |
| 2022 | 21.16 Million USD | -17.17% |
| 2021 | 25.55 Million USD | 29.04% |
| 2020 | 19.8 Million USD | 25.59% |
| 2019 | 15.76 Million USD | -44.11% |
| 2018 | 28.2 Million USD | 33.67% |
| 2017 | 21.1 Million USD | 29.18% |
| 2016 | 16.33 Million USD | 41.89% |
| 2015 | 11.51 Million USD | 81.59% |
| 2014 | 6.34 Million USD | 40.33% |
| 2013 | 4.51 Million USD | 6.56% |
| 2012 | 4.24 Million USD | 14.91% |
| 2011 | 3.69 Million USD | -8.09% |
| 2010 | 4.01 Million USD | 106.0% |
| 2009 | 1.94 Million USD | 166.52% |
| 2008 | -2.93 Million USD | 31.59% |
| 2007 | -4.28 Million USD | -530.78% |
| 2006 | -679 Thousand USD | -260.9% |
| 2005 | 422 Thousand USD | -63.53% |
| 2004 | 1.15 Million USD | -94.4% |
| 2003 | 20.66 Million USD | 2380.67% |
| 2002 | 833 Thousand USD | 395.39% |
| 2001 | -282 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 13.14 Million USD | -8.57% |
| 2024 Q2 | 14.38 Million USD | 21.1% |
| 2024 Q1 | 11.87 Million USD | 16.94% |
| 2023 FY | 37.08 Million USD | 75.21% |
| 2023 Q1 | 7.87 Million USD | 42.9% |
| 2023 Q2 | 9.45 Million USD | 20.04% |
| 2023 Q3 | 9.18 Million USD | -2.88% |
| 2023 Q4 | 10.15 Million USD | 10.61% |
| 2022 FY | 21.16 Million USD | -17.17% |
| 2022 Q2 | 5.78 Million USD | 2.14% |
| 2022 Q1 | 5.66 Million USD | -31.78% |
| 2022 Q4 | 5.51 Million USD | 34.85% |
| 2022 Q3 | 4.08 Million USD | -29.36% |
| 2021 Q2 | 11.1 Million USD | 39.79% |
| 2021 Q3 | 9.07 Million USD | -18.31% |
| 2021 FY | 25.55 Million USD | 29.04% |
| 2021 Q4 | 8.3 Million USD | -8.51% |
| 2021 Q1 | 7.94 Million USD | -16.76% |
| 2020 Q3 | 10.01 Million USD | 105.62% |
| 2020 FY | 19.8 Million USD | 25.59% |
| 2020 Q4 | 9.54 Million USD | -4.72% |
| 2020 Q1 | 4.35 Million USD | -11.67% |
| 2020 Q2 | 4.87 Million USD | 11.92% |
| 2019 Q1 | 4.43 Million USD | -38.34% |
| 2019 Q3 | 5.9 Million USD | -0.17% |
| 2019 Q4 | 4.92 Million USD | -16.55% |
| 2019 FY | 15.76 Million USD | -44.11% |
| 2019 Q2 | 5.91 Million USD | 33.37% |
| 2018 Q3 | 4.61 Million USD | -60.03% |
| 2018 Q1 | 4.86 Million USD | -23.09% |
| 2018 FY | 28.2 Million USD | 33.67% |
| 2018 Q4 | 7.19 Million USD | 55.93% |
| 2018 Q2 | 11.54 Million USD | 137.37% |
| 2017 FY | 21.1 Million USD | 29.18% |
| 2017 Q4 | 6.32 Million USD | 25.11% |
| 2017 Q3 | 5.05 Million USD | -8.72% |
| 2017 Q2 | 5.53 Million USD | 32.03% |
| 2017 Q1 | 4.19 Million USD | 7.27% |
| 2016 FY | 16.33 Million USD | 41.89% |
| 2016 Q3 | 5.34 Million USD | 41.26% |
| 2016 Q2 | 3.78 Million USD | 14.64% |
| 2016 Q4 | 3.9 Million USD | -26.85% |
| 2016 Q1 | 3.3 Million USD | 6.83% |
| 2015 Q4 | 3.08 Million USD | -6.99% |
| 2015 FY | 11.51 Million USD | 81.59% |
| 2015 Q3 | 3.32 Million USD | 18.86% |
| 2015 Q2 | 2.79 Million USD | 21.0% |
| 2015 Q1 | 2.3 Million USD | -15.7% |
| 2014 Q3 | 1.85 Million USD | -6.46% |
| 2014 Q4 | 2.73 Million USD | 47.89% |
| 2014 FY | 6.34 Million USD | 40.33% |
| 2014 Q1 | -231 Thousand USD | -119.71% |
| 2014 Q2 | 1.98 Million USD | 957.14% |
| 2013 Q3 | 776 Thousand USD | -46.37% |
| 2013 Q4 | 1.17 Million USD | 51.03% |
| 2013 Q1 | 1.12 Million USD | 20.75% |
| 2013 FY | 4.51 Million USD | 6.56% |
| 2013 Q2 | 1.44 Million USD | 28.85% |
| 2012 Q3 | 1 Million USD | -31.2% |
| 2012 Q4 | 930 Thousand USD | -7.09% |
| 2012 Q2 | 1.45 Million USD | 70.37% |
| 2012 Q1 | 854 Thousand USD | 2.64% |
| 2012 FY | 4.24 Million USD | 14.91% |
| 2011 FY | 3.69 Million USD | -8.09% |
| 2011 Q1 | -30 Thousand USD | 97.68% |
| 2011 Q2 | 897 Thousand USD | 3090.0% |
| 2011 Q3 | 1.99 Million USD | 121.96% |
| 2011 Q4 | 832 Thousand USD | -58.21% |
| 2010 Q3 | 2.03 Million USD | 1.2% |
| 2010 Q4 | -1.29 Million USD | -163.73% |
| 2010 FY | 4.01 Million USD | 106.0% |
| 2010 Q1 | 1.27 Million USD | 3.34% |
| 2010 Q2 | 2 Million USD | 58.11% |
| 2009 Q2 | 993 Thousand USD | 163.41% |
| 2009 Q1 | -1.56 Million USD | -541.13% |
| 2009 FY | 1.94 Million USD | 166.52% |
| 2009 Q4 | 1.22 Million USD | -4.95% |
| 2009 Q3 | 1.29 Million USD | 30.21% |
| 2008 FY | -2.93 Million USD | 31.59% |
| 2008 Q2 | -869 Thousand USD | 66.4% |
| 2008 Q3 | 170 Thousand USD | 119.56% |
| 2008 Q4 | 355 Thousand USD | 108.82% |
| 2008 Q1 | -2.58 Million USD | -96.36% |
| 2007 FY | -4.28 Million USD | -530.78% |
| 2007 Q4 | -1.31 Million USD | 14.54% |
| 2007 Q2 | -447 Thousand USD | 54.25% |
| 2007 Q3 | -1.54 Million USD | -244.74% |
| 2007 Q1 | -977 Thousand USD | -125.64% |
| 2006 Q1 | 462 Thousand USD | 102.16% |
| 2006 Q4 | -433 Thousand USD | -226.24% |
| 2006 FY | -679 Thousand USD | -260.9% |
| 2006 Q3 | 343 Thousand USD | 132.64% |
| 2006 Q2 | -1.05 Million USD | -327.49% |
| 2005 Q3 | 7.82 Million USD | 3.85% |
| 2005 Q4 | -21.43 Million USD | -374.05% |
| 2005 Q2 | 7.53 Million USD | 0.39% |
| 2005 FY | 422 Thousand USD | -63.53% |
| 2005 Q1 | 7.5 Million USD | 141.57% |
| 2004 FY | 1.15 Million USD | -94.4% |
| 2004 Q4 | -18.04 Million USD | -375.68% |
| 2004 Q1 | 6.54 Million USD | 0.0% |
| 2004 Q3 | 6.54 Million USD | 0.0% |
| 2004 Q2 | 6.54 Million USD | 0.0% |
| 2003 FY | 20.66 Million USD | 2380.67% |
| 2002 FY | 833 Thousand USD | 395.39% |
| 2001 FY | -282 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 164.303% |
| AngioDynamics, Inc. | -97.71 Million USD | 137.948% |
| AtriCure, Inc. | -26.68 Million USD | 238.972% |
| Avinger, Inc. | -16.63 Million USD | 322.916% |
| Azenta, Inc. | -73.12 Million USD | 150.71% |
| BioLife Solutions, Inc. | -70.82 Million USD | 152.357% |
| The Cooper Companies, Inc. | 533.1 Million USD | 93.044% |
| Daxor Corporation | -177.07 Thousand USD | 21041.409% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 345.381% |
| Femasys Inc. | -14.5 Million USD | 355.59% |
| GlucoTrack, Inc. | -7.1 Million USD | 621.988% |
| Harvard Bioscience, Inc. | 1.89 Million USD | -1857.867% |
| Hologic, Inc. | 882.6 Million USD | 95.799% |
| ICU Medical, Inc. | 22.82 Million USD | -62.462% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 97.901% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 461.072% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 637.378% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 637.378% |
| Masimo Corporation | 136.5 Million USD | 72.834% |
| Microbot Medical Inc. | -9.85 Million USD | 476.276% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | -152.689% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 70.082% |
| Nephros, Inc. | -1.59 Million USD | 2427.809% |
| NovoCure Limited | -232.87 Million USD | 115.924% |
| NEXGEL, Inc. | -3.47 Million USD | 1166.494% |
| NEXGEL, Inc. | -3.47 Million USD | 1166.494% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 136.072% |
| OraSure Technologies, Inc. | 54.07 Million USD | 31.43% |
| Pro-Dex, Inc. | 7.17 Million USD | -416.966% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 185.101% |
| Predictive Oncology Inc. | -13.92 Million USD | 366.368% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | 1461.141% |
| QuidelOrtho Corporation | 139.1 Million USD | 73.341% |
| Repligen Corporation | 54.57 Million USD | 32.054% |
| Sanara MedTech Inc. | -4.21 Million USD | 979.731% |
| STAAR Surgical Company | 28.09 Million USD | -31.979% |
| Sharps Technology, Inc. | -10.12 Million USD | 466.182% |
| Utah Medical Products, Inc. | 16.77 Million USD | -121.029% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 143.626% |
| Jin Medical International Ltd. | 2.86 Million USD | -1193.29% |